ITEM 7.01 REGULATION FD DISCLOSURE
Alzamend Neuro, Inc. (the "Company") updated its investor presentation (the
"Corporate Presentation"), which is used to conduct meetings with investors,
stockholders and analysts and at investor conferences, which may contain
nonpublic information. A copy of the Corporate Presentation, which is furnished
herewith as Exhibit 99.1, is incorporated by reference herein. The Corporate
Presentation provides, among other things, an overview of the Company's
therapeutic drugs for the treatment of neurodegenerative diseases and
psychiatric disorders, including Alzheimer's.
In accordance with General Instruction B.2 of Form 8-K, the information under
this item and Exhibit 99.1 shall not be deemed filed for purposes of Section 18
of the Securities Exchange Act of 1934, as amended, nor shall such information
be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, except as shall be expressly set forth by specific reference
in such a filing. This report will not be deemed an admission as to the
materiality of any information required to be disclosed solely to satisfy the
requirements of Regulation FD.
The Securities and Exchange Commission encourages registrants to disclose
forward-looking information so that investors can better understand the future
prospects of a registrant and make informed investment decisions. This Current
Report on Form 8-K and exhibits may contain these types of statements, which are
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, and which involve risks, uncertainties and
reflect the Registrant's judgment as of the date of this Current Report on Form
8-K. Forward-looking statements may relate to, among other things, operating
results and are indicated by words or phrases such as "expects," "should,"
"will," and similar words or phrases. These statements are subject to inherent
uncertainties and risks that could cause actual results to differ materially
from those anticipated at the date of this Current Report on Form 8-K. Investors
are cautioned not to rely unduly on forward-looking statements when evaluating
the information presented within.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits:
Exhibit No. Description
99.1 Corporate Presentation.
101 Pursuant to Rule 406 of Regulation S-T, the cover page is
formatted in Inline XBRL (Inline eXtensible Business Reporting
Language).
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document and included in Exhibit 101).
-2-
© Edgar Online, source Glimpses